Does metoclopramide cause QTc (QT interval corrected) prolongation?

Metoclopramide and QTc Prolongation

Metoclopramide can cause QTc prolongation and potentially contribute to torsades de pointes, especially when used in combination with other QT-prolonging medications. 1

Evidence of QTc Prolongation

• Metoclopramide is specifically listed as an antiemetic that increases the risk of QT prolongation in clinical guidelines 2
• A case report documented torsades de pointes in a patient on methadone therapy who received metoclopramide and metronidazole, demonstrating the potential for serious arrhythmias when QT-prolonging medications are combined 1
• Experimental research in a whole-heart model showed that metoclopramide led to significant increases in action potential duration and QT interval, with higher doses significantly increasing the number of ventricular tachycardias 3

Risk Factors for QTc Prolongation with Metoclopramide

• Concomitant use with other QT-prolonging medications significantly increases risk 2
• Electrolyte abnormalities, particularly hypokalemia, hypomagnesemia, or hypocalcemia 2
• Older age and female sex 2
• Underlying heart disease, especially left ventricular hypertrophy, ischemia, or low ejection fraction 2
• Slow heart rate or bradyarrhythmias 2
• Genetic predisposition to QT prolongation 2

Monitoring Recommendations

• Obtain baseline ECG before initiating treatment with metoclopramide if the patient has other risk factors for QT prolongation 2, 4
• Document QTc in the patient's medical record using a rhythm strip before drug initiation and at least every 8 hours during treatment 2
• Use the same ECG lead for QT measurements over time for consistency 2
• Consider using Fridericia's formula (QTcF = QT/∛RR) rather than Bazett's formula for heart rate correction, especially at higher heart rates 2, 4

Management of QTc Prolongation

• If QTc reaches >500 ms or increases by >60 ms compared to baseline, treatment with metoclopramide should be discontinued or the dose reduced 2, 4
• Correct any electrolyte abnormalities, particularly hypokalemia and hypomagnesemia 2, 4
• Avoid concomitant use of multiple QT-prolonging medications 2
• Exercise particular caution in elderly patients and those with structural heart disease 2, 4

High-Risk Combinations to Avoid

• Metoclopramide with bedaquiline (specifically listed as a contraindicated combination) 2
• Metoclopramide with methadone (documented case of torsades de pointes) 1
• Metoclopramide with antiarrhythmics (quinidine, procainamide, disopyramide, sotalol, etc.) 2
• Metoclopramide with other QT-prolonging drugs such as certain antipsychotics, antidepressants, and fluoroquinolones 2

Clinical Implications

• The risk of QTc prolongation with metoclopramide appears dose-dependent, with higher doses carrying greater risk 3
• Patients with neurological conditions may be particularly vulnerable to QTc prolongation when receiving metoclopramide 5
• Careful monitoring is especially important when metoclopramide is used in patients with cancer pain who may be receiving multiple medications 2

While metoclopramide is not among the most potent QT-prolonging medications, clinicians should be aware of its potential to contribute to QTc prolongation, especially in vulnerable patients or when combined with other QT-prolonging drugs.